Kyverna Therapeutics (KYTX) filed a registration statement late Thursday for the sale of up to $300 million of securities.

The shelf covers common and preferred stock, debt securities, warrants, rights, units, and depositary shares.

Net proceeds will be used for general corporate purposes, the company said.